Claims

1. Use of a composition in the manufacture of a medicament for treating moderate atopic dermatitis with a local SCORAD score of at least 6, wherein the medicament is to be topically applied on the skin at least 2 times a day, wherein the composition has a pH in the range of 2.7 to 5.0 and wherein the composition comprises

a polyhydroxy acid and a zinc salt of its conjugate base, wherein the polyhydroxy acid is selected from lactobionic acid, gluconolactone, or a combination of lactobionic acid and gluconolactone,

a partition coefficient enhancer selected from propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, 1,5 pentane diol or a combination thereof,

a diffusion coefficient enhancer which is a C14 straight chain primary alcohol,

and wherein the composition is free of steroids.

2. Use of a composition in the manufacture of a medicament for treating atopic dermatitis, wherein the medicament is to be topically applied on the skin for between 10 and up to 28 days at least 2 times a day, wherein the composition has a pH in the range of 2.7 to 5.0 and wherein the composition comprises

a polyhydroxy acid and a zinc salt of its conjugate base, wherein the polyhydroxy acid is selected from lactobionic acid, gluconolactone, a combination of lactobionic acid and gluconolactone,

a partition coefficient enhancer selected from propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, 1,5 pentane diol or a combination thereof,

a diffusion coefficient enhancer which is a C14 straight chain primary alcohol,

and wherein the composition is free of steroids.

3. The use according to claim 2, wherein the atopic dermatitis is moderate or mild atopic dermatitis.

4. The use according to any one of the preceding claims, wherein the medicament is to be applied twice daily.

5. The use according to any one of the preceding claims, wherein the composition is free of topical calcineurin inhibitors and/or wherein the treatment of atopic dermatitis does not include treatment with a topical calcineurin inhibitor or other pharmaceutical active.

6. The use according to any one of the preceding claims, wherein the composition is to be topically applied for 12 days and 20 days, for example, about 14 days.

7. The use according to any one of the preceding claims, wherein the local SCORAD score of the atopic dermatitis at the start of treatment is at least 6, preferably between 6 and 12, for example, between 6 and 10.

8. The use according to any one of the preceding claims, wherein the treatment involves identifying a patient suffering from moderate atopic dermatitis by measuring the local SCORAD score, determining that the local SCORAD score is at least 6, more preferably between 6 and 12,
   optionally wherein the treatment further comprises measuring the local SCORAD score after a time period to ensure whether further treatment is needed, and
   further optionally, wherein the time period is less than 4 weeks, or less than or equal to 3 weeks, or less than or equal to 2 weeks.

9. The use according to any one of the preceding claims, wherein use results in a reduction of local SCORAD score (ΔSCORAD) of at least 1, or at least 2, or at least 3, or at least 4 compared to baseline local SCORAD at the start of treatment, optionally wherein the reduction in local SCORAD score is obtained in less than 4 weeks, or less than or equal to 3 weeks, or less than or equal to 2 weeks.

10. The use according to any one of the preceding claims, wherein the pH of the composition is between 3.0 to 4.0, more preferably from 3.0 to 3.5, and even more preferably about 3.2.

11. The use according to any one of the preceding claims, wherein the partition coefficient enhancer is butylene glycol and/or wherein the partition coefficient enhancer is present in an amount that is 15-30% w/w of the composition, or from 15-25% w/w of the composition, or from 15-20% w/w of the composition.

12. The use according to any one of the preceding claims, wherein the diffusion coefficient enhancer is present in an amount that is 1.0-2.0 % w/w of the composition, 1.2-1.8 % w/w or about 1.5% w/w of the composition.

13. The use according to any one of the preceding claims, wherein the composition further comprises a ceramide, preferably wherein the ceramide is present in an amount from 0.5 to 1.5% w/w of the composition.

14. The use according to any one of the preceding claims, wherein the composition comprises
(i) from 3-6% w/w methyl glucose sesquistearate and 1-2% w/w PEG-20 methyl glucose sesquistearate, and/or
(ii) a PEG-240/HDI copolymer bis-decyltetradeceth-20 ether, and/or
(iii) an acrylates/C10-C30 alkyl acrylate copolymer.

15. The use according to any one of the preceding claims, wherein the composition comprises
4-6 % w/w polyhydroxy acid and zinc salt of its conjugate base, wherein the polyhydroxy acid is lactobionic acid,
15-20% w/w partition coefficient enhancer, preferably butylene glycol,
1-2% w/w diffusion coefficient enhancer, preferably tetradecyl alcohol, and
10-20% w/w emollient, preferably hydrogenated polydecene,
3-12 % w/w surfactant, preferably wherein the surfactant comprises one or more of methyl glucose sesquistearate, PEG-20 methyl glucose sesquistearate, glyceryl stearate or a combination thereof,
40-60% w/w water, and
up to 3% w/w humectant, preferably glycerol, and
optionally a co-surfactant, preferably in an amount up to 6% w/w of the composition,
optionally a ceramide, preferably in an amount up to 1.5% w/w of the composition,
optionally cholesterol, preferably in an amount up to 0.5% w/w of the composition,
optionally a fatty acid, preferably in an amount up to 0.5% w/w of the composition,
optionally a PEG-240/HDI copolymer bis-decyltetradeceth-20 ether, preferably in an amount up to 1% w/w of the composition,
optionally a acrylates/C10-C30 alkyl acrylate copolymer, preferably in an amount up to 0.5% w/w of the composition, and
optionally a preservative, preferably in an amount up to 1 % w/w of the composition,
wherein the pH of the composition is between 3.0 and 3.5.